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OBJECTIVES: Improved peri- and postoperative clinical outcomes can result in 
economic savings for hospitals and payers. While the relative effectiveness of 
topical hemostatic agents in the termination of bleeding during cardiac 
operations has been demonstrated, the economic benefit has not been 
evaluated. An economic analysis quantified the reduction in costs associated 
with efficient control of intraoperative bleeding. METHODS: Based on a cost-
consequence framework, an economic model computed incremental annual 
outcomes and cost savings from use of a Hemostatic Matrix (FLOSEAL) versus 
other topical hemostatic agents. The model captured cost implications of 
acquisition, operating room time, complications, blood transfusions and surgical 
revisions due to bleeding associated with cardiac surgery procedures. Clinical 
outcomes data were from a prospective controlled study evaluating whether the 
use of a Hemostatic Matrix correlates to a decrease in postoperative bleeding-
related events and complications relative to a control group using other 
hemostatic agents in a cohort of mixed-cardiothoracic aortic procedures (Nasso 
et al., 2009). Base-case costs, expressed in 2012 USD, were obtained through US 
cost database analyses and literature. Surgery and care related costs were 
regionally adjusted by economically influenced wage indices. Cost savings were 
determined based on a hypothetical annual number of cases. RESULTS: Effective 
hemostasis with a Hemostatic Matrix, when compared with a control group, 
results in cost savings through reduced OR time, reduced need for surgical 
revision, fewer blood transfusions and fewer post-operative complications. For a 
facility that conducts 600 cardiac surgeries annually, the net annualized cost 
savings is $5.2 million with the reduction in complications contributing the 
largest portion of the savings. CONCLUSIONS: The present economic model is 
reliable in evaluating hospital cost fluctuations associated with the use of 
hemostatic agents in cardiac surgery. These analyses strongly indicate 
significant savings if the Hemostatic Matrix is routinely employed in a cohort of 
mixed cardiothoracic aortic surgical procedures.  
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OBJECTIVES: Transcatheter radiofrequency ablation (RFA) is one of the primary 
treatments for symptomatic drug-refractory atrial fibrillation (AF) and it is 
considered the first-line therapy for other arrhythmias. One of the major 
complications of procedure is cardiac perforation and tamponade, which can 
occur in cardiac chambers. Contact force technology is an important predictor of 
RFA efficacy and safety, a cost-consequence analysis between standard ablation 
catheter and Thermocool®SmartTouch™ catheter for RFA of AF has been 
developed in order to evaluate the introduction of the contact force in clinical 
practice of Terni’s hospital. METHODS: An excel model was developed to 
simulate a cost-consequence analysis based on literature review and 
economic/organizative data collection. The means, standard deviation and 95% 
confidence intervals for the analysis were estimated using Bayesian methods 
(10,000 simulations) and assuming a reduction in terms of procedure time, 
complications and recurrence with the use of Thermocool®SmartTouch™ 
catheter. The analysis estimated the cost per procedure and per patient from 
hospital perspective in 1 year time horizon. RESULTS: The average total cost 
(including consumables, room, personnel and complications costs) was 
estimated at 9,201€ (95%IC 7,629-11,251€) for Thermocool® SmartTouch™ 
procedure and 9,460€ (95%IC 7,885-11,577€) for standard procedure. The 
consequences were estimated as procedure cost per patient, assuming the re-
treatment reduction with Thermocool® SmartTouch™. The procedure cost per 
patient was estimated at 11,501€ (95%IC 9,234-14,602€) with Thermocool® 
SmartTouch™ and at 13,515€ (95%IC 10,883-17,324€) with standard. Moreover, 
both procedure and fluoroscopy time have been calculated respectively: 199 and 
40 minutes for Thermocool®SmartTouch™ catheter vs 284 and 57 minutes for 
standard catheter. CONCLUSIONS: Thermocool® SmartTouch™ technology 
appears cost-savings and the consequences management results to be favorable. 
The results were consistent according to the developed probabilistic sensitivity 
analysis, but they could be different in real clinical practice, therefore it is 
necessary to collect data after Thermocool® SmartTouch™ introduction for 
validating the results simulated.  
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OBJECTIVES: To determine the cost-effectiveness of using a platelet reactivity 
assay (PRA) to aid in the selection between dual antiplatelet treatment strategies 
for acute coronary syndrome (ACS) patients. METHODS: A hybrid decision 
tree/Markov model was used to calculate 5-year costs (2011 US$), quality-
adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) of 
1-year of universal clopidogrel, ticagrelor or prasugrel (given to all patients) or 
PRA-driven ticagrelor or prasugrel (given to patients with high platelet reactivity 
defined as >230 on the VerifyNow P2Y12 assay, others got generic clopidogrel). 
We assumed a cohort of 65-year-old ACS patients and 32% and 13% incidences of 
high platelet reactivity ~24-48 hours post-revascularization and at 1-month. The 
analysis was conducted from a US payer perspective and used a 1-year cycle 
length. Data depicting the efficacy and safety of dual antiplatelet treatment were 
taken from randomized trials. RESULTS: The PRA-driven ticagrelor and prasugrel 
strategies were cost-effective compared to universal clopidogrel (ICERs=$40,100 
and $49,143/QALY); however, universal ticagrelor and prasugrel strategies were 
not (ICERs=$61,651 and $96,261/QALY). Monte Carlo simulation suggested PRA-
driven ticagrelor, PRA-driven prasugrel, universal ticagrelor and universal 
prasugrel would have ICERs<$50,000/QALY (be cost-effective) in 52%, 40%, 23%, 
and 2% of 10,000 iterations versus universal clopidogrel. Universal ticagrelor or 
prasugrel were also not found to be cost-effective strategies compared to the 
PRA-driven use of these same agents (ICERs=$68,182 and $116,875/QALY, 
respectively). Monte Carlo simulation suggested universal selection of ticagrelor 
and prasugrel would have ICERs<$50,000/QALY in only 26% and 4% of 10,000 
iterations compared to their PRA-driven use. The model’s conclusions were most 
sensitive to differences in antiplatelet agent costs and drug-specific relative risks 
of death. CONCLUSIONS: Even in the age of generic clopidogrel, PRA-driven 
selection of antiplatelet therapy appears to be a cost-effective strategy with the 
potential to decrease overall ACS associated health care costs.  
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OBJECTIVES: Ticagrelor has been shown to reduce acute coronary syndrome 
(ACS)-related complications, but with a higher incidence of bleeding and greater 
acquisition cost than generic clopidogrel. This study was designed to assess the 
cost-effectiveness of ticagrelor use compared with clopidogrel in ACS patients 
from the US health system perspective. METHODS: A decision model was 
developed and the probabilities of complications including myocardial infarction 
(MI), ischemic stroke (IS), vascular death, and major bleeding events were 
defined based on the Platelet Inhibition and Patient Outcomes (PLATO) trial and 
sub studies. Cost inputs were identified from a systematic literature review and 
from Healthcare Cost and Utilization Project (HCUP) databases. Life expectancy 
for PLATO population was estimated using DEALE method. All costs were 
adjusted to 2012 US dollars. Utility estimates for complications were identified 
from peer reviewed studies, and quality-adjusted life years (QALYs) were 
projected to measure effectiveness. Lifetime costs and cost-effectiveness were 
calculated. One-way sensitivity analyses were performed on all variables. 
RESULTS: In the base case analysis, ticagrelor treatment ($58,922.91 and 10.2579 
QALYs) provided 0.1243 more QALYs but cost $23,566.60 more than clopidogrel 
($35,366.30 and 10.1336 QALYs). The incremental cost-effectiveness ratio (ICER) 
for the ticagrelor treatment was $189,468.79/QALY. Results were sensitive to the 
cost (50% to 200% range) of ticagrelor ($57,167.95 to $454,066.84 per QALY), the 
cost of clopidogrel ($228,166.51 to $112,069.80 per QALY), and the hazard ratio 
(95% confidence interval range) of vascular death ($135,710.24 to $358,837.65 per 
QALY). The ICER was less than $100,000/QALY only if the daily acquisition cost of 
ticagrelor was lower than $4.88 (i.e., about 66% of the daily cost in the base case). 
CONCLUSIONS: At its current price, ticagrelor was not a cost-effective treatment 
strategy in patients with ACS compared to generic clopidogrel, using either 
$50,000 or $100,000/QALY as the ICER threshold.  
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OBJECTIVES: Type-2 diabetes in France has increased in prevalence over the past 
decade and there is a need to examine cardiovascular outcomes based on real-
world evidence (RWE). The CANARD model was developed to evaluate the cost-
effectiveness (CE) of treatments using data from a RWE French population in the 
IMS LifeLinkTM Diabetes Cohort database. METHODS: A Markov micro-simulation 
model was developed in Microsoft Excel 2007® using the United Kingdom 
Prospective Diabetes Study (UKPDS) risk equations to predict cardiovascular 
outcomes (MI, stroke, death). Four treatment pathways taken from the IMS 
LifeLinkTM Diabetes Cohort database were evaluated, which included step-wise 
treatment switches based on the patient’s HbA1c. Treatments within the 
pathway included diet and exercise, metformin (MF), oral anti-diabetics (OADs) 
of sulfonylurea (SU) or dipeptidyl peptidase IV (DDP-IV) in addition to MF, a lipid 
lowering agent (atorvastatin) in addition to MF and an OAD, and insulin. CE 
outcomes in 13 subgroups were explored and uncertainty in the model was 
evaluated with a probabilistic sensitivity analysis (PSA) and expected value of 
perfect information (EVPI). The model was validated by comparing the predicted 
results to the database results at 18 months. RESULTS: The results showed that 
the treatment pathway including SU with atorvastatin was the most cost-
effective in the general population at €2,640/QALY. The results from the PSA 
showed that the likelihood of this treatment pathway being cost-effective was 
0.61 at willingness-to-pay (WTP) of €20,000/QALY, and 0.56 at a WTP of 
€50,000/QALY. EVPI at a WTP of €20,000/QALY and €50,000/QALY were €476 per 
patient and €1,427 per patient respectively. The subgroup results demonstrated 
that depending on the WTP of the French National Health Service, several 
treatments pathways may be CE. CONCLUSIONS: Overall, SU with atorvastatin 
was the most cost-effective treatment for a French type II diabetic population, 
however, uncertainty was evident and therefore, future research would be of 
value.  
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